Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing

Area of Science:

• Oncology
• Molecular Biology
• Gene Editing

Background:

• KRAS mutations are prevalent in human cancers, driving tumor growth and representing key therapeutic targets.
• CRISPR-Cas9 has emerged as a tool for targeting KRAS mutations, but can lead to the development of resistant cancer cell variants.

Purpose of the Study:

• To investigate the efficacy of base editors in correcting oncogenic KRAS mutations and assess their potential for cancer therapy.
• To compare base editing with CRISPR-Cas9 in targeting KRAS mutations and evaluate the emergence of resistance.

Main Methods:

• Utilized CRISPR-Cas9 to cleave KRAS driver mutations in cancer cell lines, observing growth suppression and resistance.
• Employed adenine base editors to correct oncogenic KRAS mutations, monitoring for cell depletion and escape variants.
• Simultaneously corrected KRAS and TP53 mutations using base editing in patient-derived cancer organoids.

Main Results:

• CRISPR-Cas9-mediated cleavage of KRAS mutations suppressed cancer cell growth but resulted in the emergence of Cas9-resistant KRAS escape variants.
• Adenine base editing progressively depleted KRAS-mutant cells without generating escape variants.
• Simultaneous base editing of oncogenic KRAS and TP53 mutations was achieved in cancer organoids.

Conclusions:

• Base editors provide a more robust approach than CRISPR-Cas9 for targeting KRAS mutations, avoiding resistance.
• Base editing facilitates simultaneous correction of multiple oncogenic mutations, offering potential for personalized precision oncology.
• This study highlights the therapeutic potential of base editors for understanding RAS biology and developing novel treatments for KRAS-mutant cancers.